Literature DB >> 28817211

Reviewing the ICS 2002 terminology report: The ongoing debate.

Paul Abrams1, Walter Artibani, Linda Cardozo, Roger Dmochowski, Philip van Kerrebroeck, Peter Sand.   

Abstract

Year:  2006        PMID： 28817211     DOI： 10.1002/nau.20251

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN： 0733-2467            Impact factor:   2.696


× No keyword cloud information.
  14 in total

1.  Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status.

Authors:  Marc R Toglia; Donald R Ostergard; Rodney A Appell; Masakazu Andoh; Allam Fakhoury; Iqbal F Hussain
Journal:  Int Urogynecol J       Date:  2010-03-26       Impact factor: 2.894

2.  Does conservative management really benefit patients with OAB?

Authors:  Philip E V Van Kerrebroeck
Journal:  Curr Urol Rep       Date:  2012-10       Impact factor: 3.092

3.  The prevalence of urinary incontinence in American Indian women from a South Dakota tribe.

Authors:  Michael M Fiegen; Kevin D Benson; Jessica D Hanson; Jennifer Prasek; Keith A Hansen; Peter VanEerden
Journal:  Int Urogynecol J       Date:  2011-12-13       Impact factor: 2.894

Review 4.  Urinary urgency: a review of its assessment as the key symptom of the overactive bladder syndrome.

Authors:  Paul Abrams; Christopher R Chapple; Klaus-Peter Jünemann; Steven Sharpe
Journal:  World J Urol       Date:  2011-08-19       Impact factor: 4.226

5.  Management of fluid intake in patients with overactive bladder.

Authors:  Hashim Hashim; Riyad Al Mousa
Journal:  Curr Urol Rep       Date:  2009-11       Impact factor: 3.092

6.  Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women.

Authors:  Rebecca Rogers; Gloria Bachmann; Zhanna Jumadilova; Franklin Sun; Jon D Morrow; Zhonghong Guan; Tamara Bavendam
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-08-07

7.  Continued symptom improvement in sexually active women with overactive bladder and urgency urinary incontinence treated with tolterodine ER for 6 months.

Authors:  Rebecca G Rogers; Tola Omotosho; Gloria Bachmann; Franklin Sun; Jon D Morrow
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2009-01-09

8.  Evaluation of drug-drug interactions with fesoterodine.

Authors:  Bimal Malhotra; Richard Sachse; Nolan Wood
Journal:  Eur J Clin Pharmacol       Date:  2009-04-04       Impact factor: 2.953

9.  Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX study.

Authors:  Laura T Pizzi; Amy Talati; Eric Gemmen; Naomi V Dahl; Thomas J Bunz; Peter K Sand
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

10.  Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment: An open-label, flexible-dosing, multicentre study.

Authors:  Steven E Swift; Paul Siami; Sergio Forero-Schwanhaeuser
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.